Medicaid VBPs for Patients Act

This bill allows Medicaid programs to enter into value-based purchasing (VBP) arrangements with drug manufacturers for innovative treatments like gene therapies. It codifies these arrangements by requiring states to report pricing structures based on patient outcomes and best prices for drugs sold under these agreements. The bill enables payments to be tied to treatment effectiveness, potentially reducing long-term healthcare costs by decreasing hospitalizations and other medical expenses. It also creates a requirement for a GAO study to evaluate how these arrangements impact patient access, outcomes, and healthcare system costs. The bill will sunset after 5 years, though existing VBP arrangements will continue beyond that date.